Αρχική World News Neoadjuvant Nivolumab/Relatlimab Induces High Rates of Pathologic Responses in Patients with Locally... World News Neoadjuvant Nivolumab/Relatlimab Induces High Rates of Pathologic Responses in Patients with Locally Advanced MMR-deficient Colon Cancer Από Ogkologos - 22 Νοεμβρίου, 2024 880 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NICHE-3 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Vaping Pods Produce High Nicotine Levels in Young Users 5 Οκτωβρίου, 2018 Age and Frailty Should Be Considered Independently When Evaluating Potential Risk... 27 Ιουνίου, 2022 Doctor Wipes Away The Debt Of 200 Cancer Patients 6 Ιανουαρίου, 2021 ‘Family Haven’ Gives Homeless Parents & Their Kids Hope And A... 29 Δεκεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Puppy That Was Born Dead Becomes Therapy Dog for Cancer Patient High-Dose Chemotherapy Followed by ASCT Improves Survival Compared with Non-myeloablative Consolidation... EMA Recommends Extending Indications for Lisocabtagene Maraleucel Epigenetic Changes Pinpointed as the Cause of Some GISTs